report utility molecular epidemiologic approach common polygenic diseases NUMBER angiotensin enzyme ace dd genotype linked cardiovascular diseases including diabetic nephropathy earlier ace genotype associated excess tissue ace activity observed association ace genotype large number common diseases including chronic renal failure diabetes mellitus hypertension hypertensive peripheral vascular disease emphysema chronic obstructive pulmonary disease copd ace inhibitors clinical use NUMBER safety record armed knowledge ace overactivity associated disease gave intended tissue dose hydrophobic ace inhibitor NUMBER caucasian male patients hypertension NUMBER caucasian male patients chronic renal failure period NUMBER years report outcomes include patients hypertensive peripheral vascular disease patient emphysema copd group outcomes superior available literature experience suggests power pharmacogenomics improve clinical outcomes common diseases safely quickly inexpensively effective drugs exist converting non insulin dependent known ace inhibitory african american african american end stage end stage deletion deletion d d d d